PMID: 15389998DOI: 10.1002/mds.20164Sep 25, 2004Paper
Reversible Pisa syndrome (pleurothotonus) due to the cholinesterase inhibitor galantamine: case report
Movement Disorders : Official Journal of the Movement Disorder Society
Giovanni CossuPaolo Francesco Putzu
Abstract
We report on a case of reversible Pisa syndrome developed after treatment with galantamine in a patient with Alzheimer's disease without previous exposure to neuroleptic or other cholinesterase inhibitors. Complete and persistent resolution of the syndrome was achieved several weeks after botulinum toxin type-A injection.
References
Nov 1, 1975·Journal of Psychiatric Research·M F FolsteinP R McHugh
Dec 1, 1990·Acta Psychiatrica Scandinavica·T SuzukiT Hori
Nov 1, 1986·The American Journal of Psychiatry·N GuyM Assael
Jan 1, 1972·Zeitschrift für Neurologie·K EkbomL Ljungberg
Jul 1, 1984·Neurology·G McKhannE M Stadlan
Jul 1, 1997·Journal of Geriatric Psychiatry and Neurology·P N TariotR Hamill
Oct 27, 1997·Neurology·K MeguroA Yamadori
Jun 5, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·C Colosimo
Jul 6, 2000·Lancet·Y T KwakM S Koo
Dec 5, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·K F BhattacharyaK R Chaudhuri
Aug 8, 2001·The Journal of Clinical Psychiatry·T MiyaokaJ Horiguchi
Mar 13, 2002·CNS Drugs·Toshihito Suzuki, Hisashi Matsuzaka
Jun 5, 2003·Clinical Neuropharmacology·Alberto VillarejoJuan Ruiz
❮ Previous
Next ❯
Citations
Sep 19, 2009·Journal of Neurology·Andrea SantamatoPietro Fiore
Nov 17, 2010·Journal of Neurology·Alessandro Di MatteoMichele Tinazzi
Apr 26, 2011·Journal of Neurology·Marcello DeriuGiovanni Cossu
Apr 9, 2013·International Psychogeriatrics·Vikas Dhikav, Kuljeet Singh Anand
Nov 7, 2008·La Presse médicale·Dominique Huvent-GrelleFrançois Puisieux
Sep 5, 2007·Journal of the American Geriatrics Society·Dominique Huvent-GrelleFrançois Puisieux
Aug 10, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Laura BonanniMarco Onofrj
Pisa syndrome in Parkinson's disease: clinical, electromyographic, and radiological characterization
Oct 15, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Cristina TassorelliEmilia Martignoni
Oct 16, 2013·Pharmacotherapy·Anthony S ZannasP Murali Doraiswamy
Dec 18, 2014·Journal of the American Geriatrics Society·Dominique Huvent-GrelleFrançois Puisieux
Aug 30, 2016·Lancet Neurology·Paolo BaroneCarmine Vitale
Dec 23, 2008·Arquivos de neuro-psiquiatria·Quirino CordeiroHomero Vallada
Nov 13, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Sonia Brucki, Ricardo Nitrini
May 29, 2008·International Journal of Geriatric Psychiatry·Chien-Fang ChenYu-Chung Lin
Sep 15, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Mattia GambarinMichele Tinazzi
May 15, 2020·BMC Neurology·Yu MimuraMichitaka Funayama
Aug 28, 2015·Medicine·Maria Cristina B Diaz, Raymond L Rosales
May 9, 2012·Journal of Clinical Psychopharmacology·Alexandra KaufmannAlex Hofer
Jul 1, 2015·Spine Deformity·Farhad FaridhosseiniAslan Baradaran
Feb 9, 2017·Current Neurology and Neuroscience Reports·Giovanni Cossu, Carlo Colosimo
Nov 30, 2006·The Annals of Pharmacotherapy·Manu AroraSukanto Sarkar
Dec 1, 2020·Frontiers in Neurology·Jacky Ganguly, Mandar Jog
❮ Previous
Next ❯
Related Concepts
Related Feeds
Antipsychotic Drugs
Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here
Related Papers
Journal of the American Geriatrics Society
Dominique Huvent-GrelleFrançois Puisieux
Acta Neurologica Scandinavica
N VanacoreR Raschetti
Clinical Neuropharmacology
Alberto VillarejoJuan Ruiz
The Journal of Clinical Psychiatry
T MiyaokaJ Horiguchi